MIT Technology Review Subscribe

CRISPR was just used in a bid to restore sight to a blind person

The gene-editing tool CRISPR has been used for the first time inside the body of an adult patient, in an attempt to cure a form of blindness.  

The treatment: According to the Associated Press, doctors dripped just a few drops of a gene-editing mixture beneath the retina of a patient in Oregon who suffers from Leber congenital amaurosis, a rare inherited disease that leads to progressive vision loss. 

Advertisement

Cells that take up the mixture can have their DNA permanently corrected, potentially restoring a degree of vision. 

This story is only available to subscribers.

Don’t settle for half the story.
Get paywall-free access to technology news for the here and now.

Subscribe now Already a subscriber? Sign in
You’ve read all your free stories.

MIT Technology Review provides an intelligent and independent filter for the flood of information about technology.

Subscribe now Already a subscriber? Sign in

Important first: CRISPR is already being tested to modify blood cells outside the body, to treat cancer, sickle-cell disease, and other conditions. But attempting to cure diseases like muscular dystrophy or blindness, which affect tissues that can’t be removed, engineered, and replaced, requires genetically modifying cells in the body.

Previously, scientists in China modified embryos using CRISPR, leading to the controversial birth of twin girls whose bodies contain genetic modifications. As well, at least one biohacker claimed to have self-injected CRISPR. 

Commercial angle: The new study was sponsored by biotech companies Editas Medicine and Allergen and took place at Oregon Health & Science University. 

“We believe that the ability to edit inside the body is going to open entire new areas of medicine and lead to a whole new class of therapies for diseases that are not treatable any other way,” Charles Albright, chief scientific officer of Editas, told NPR.

This is your last free story.
Sign in Subscribe now

Your daily newsletter about what’s up in emerging technology from MIT Technology Review.

Please, enter a valid email.
Privacy Policy
Submitting...
There was an error submitting the request.
Thanks for signing up!

Our most popular stories

Advertisement